First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1)

This study has been terminated.
(All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.)
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01697072
First received: September 26, 2012
Last updated: January 18, 2016
Last verified: January 2016
  Purpose
This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin & capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma

Condition Intervention Phase
Gastric Cancer
Drug: Rilotumumab
Other: Placebo
Drug: Epirubicin
Drug: Cisplatin
Drug: Capecitabine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    To determine if the treatment of rilotumumab in combination with ECX significantly improves overall survival in subjects with unresectable locally advanced or metastatic MET positive gastric or GEJ cancer


Secondary Outcome Measures:
  • PFS [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Progression Free Survival (PFS)

  • TTP [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Time to Progression (TTP)

  • ORR [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Objective Response Rate (ORR)

  • DCR [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Disease Control Rate (DCR)

  • TTR [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Time to Response (TTR)

  • Safety [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Immunogenicity [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Enrollment: 609
Study Start Date: October 2012
Study Completion Date: August 2015
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rilotumumab
Rilotumumab (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
Drug: Rilotumumab
Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
Other Name: AMG102
Drug: Epirubicin
Epirubicin is an anthracycline cytotoxic agent.
Other Names:
  • Ellence
  • Pharmorubicin PFS
  • Pharmorubicin RDF
Drug: Cisplatin
Cisplatin is a non-cell cycle specific chemotherapeutic agent.
Other Names:
  • Platinol
  • Platinol-AQ
Drug: Capecitabine
Capecitabine is an oral fluoropyrimidine.
Other Name: Xeloda
Placebo Comparator: Placebo
Rilotumumab-placebo (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
Other: Placebo
Placebo
Other Name: sterile protein-free solution
Drug: Epirubicin
Epirubicin is an anthracycline cytotoxic agent.
Other Names:
  • Ellence
  • Pharmorubicin PFS
  • Pharmorubicin RDF
Drug: Cisplatin
Cisplatin is a non-cell cycle specific chemotherapeutic agent.
Other Names:
  • Platinol
  • Platinol-AQ
Drug: Capecitabine
Capecitabine is an oral fluoropyrimidine.
Other Name: Xeloda

  Eligibility

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Pathologically confirmed unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma •Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1)
  • Tumor MET-positive by immunohistochemistry (IHC)
  • Evaluable (measurable or non-measurable) disease by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria

Key exclusion criteria:

  • Human Epidermal Growth Factor Receptor 2 (HER2) -overexpressing locally advanced or metastatic gastric or GEJ adenocarcinoma •Previous systemic therapy for locally advanced or metastatic gastric or GEJ adenocarcinoma
  • Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant chemotherapy or chemoradiotherapy to randomization
  • Previous treatment with anthracyclines must not exceed total cumulative dose of epirubicin of 400 mg/m2
  • Squamous cell histology
  • Left ventricular ejection fraction (LVEF) < 50%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01697072

  Hide Study Locations
Locations
United States, Arizona
Research Site
Tucson, Arizona, United States, 85724
United States, Colorado
Research Site
Aurora, Colorado, United States, 80045
Research Site
Pueblo, Colorado, United States, 81008
United States, Illinois
Research Site
Chicago, Illinois, United States, 60637
United States, Maryland
Research Site
Baltimore, Maryland, United States, 21231
United States, Minnesota
Research Site
Woodbury, Minnesota, United States, 55125
United States, Nevada
Research Site
Henderson, Nevada, United States, 89052
United States, New York
Research Site
New York, New York, United States, 10065
Research Site
Rochester, New York, United States, 14642
United States, North Carolina
Research Site
Greensboro, North Carolina, United States, 27403
Research Site
Winston Salem, North Carolina, United States, 27103
United States, Pennsylvania
Research Site
Pittsburgh, Pennsylvania, United States, 15232
United States, Tennessee
Research Site
Nashville, Tennessee, United States, 37232
United States, Texas
Research Site
Bedford, Texas, United States, 76022
Research Site
Dallas, Texas, United States, 75246
United States, Washington
Research Site
Seattle, Washington, United States, 98109
Australia, New South Wales
Research Site
Randwick, New South Wales, Australia, 2031
Research Site
St Leonards, New South Wales, Australia, 2065
Research Site
Tweed Heads, New South Wales, Australia, 2485
Australia, Queensland
Research Site
Douglas, Queensland, Australia, 4814
Australia, South Australia
Research Site
Elizabeth Vale, South Australia, Australia, 5112
Research Site
Kurralta Park, South Australia, Australia, 5037
Australia, Victoria
Research Site
Heidelberg, Victoria, Australia, 3084
Research Site
Ringwood East, Victoria, Australia, 3135
Austria
Research Site
Graz, Austria, 8036
Research Site
Innsbruck, Austria, 6020
Research Site
Linz, Austria, 4010
Research Site
Salzburg, Austria, 5020
Research Site
Wien, Austria, 1090
Belgium
Research Site
Bruxelles, Belgium, 1180
Research Site
Bruxelles, Belgium, 1200
Research Site
Charleroi, Belgium, 6000
Research Site
Edegem, Belgium, 2650
Research Site
Liege, Belgium, 4000
Research Site
Roeselare, Belgium, 8800
Brazil
Research Site
Belo Horizonte, Minas Gerais, Brazil, 30150-321
Research Site
Pelotas, Rio Grande do Sul, Brazil, 96015-280
Research Site
Santo Andre, São Paulo, Brazil, 09060-650
Research Site
Sao Paulo, São Paulo, Brazil, 01209-000
Research Site
Sao Paulo, São Paulo, Brazil, 01509-900
Research Site
São Paulo, Brazil, 01246-000
Bulgaria
Research Site
Plovdiv, Bulgaria, 4000
Research Site
Shumen, Bulgaria, 9700
Research Site
Sofia, Bulgaria, 1233
Research Site
Sofia, Bulgaria, 1527
Research Site
Sofia, Bulgaria, 1606
Research Site
Sofia, Bulgaria, 1756
Research Site
Varna, Bulgaria, 9010
Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Research Site
London, Ontario, Canada, N6A 4L6
Research Site
Toronto, Ontario, Canada, M4C 3E7
Canada, Quebec
Research Site
Greenfield Park, Quebec, Canada, J4V 2H1
Research Site
Laval, Quebec, Canada, H7M 3L9
Research Site
Montreal, Quebec, Canada, H2L 4M1
Czech Republic
Research Site
Horovice, Czech Republic, 268 31
Research Site
Hradec Kralove, Czech Republic, 500 05
Research Site
Olomouc, Czech Republic, 775 20
Research Site
Praha 2, Czech Republic, 120 00
Research Site
Usti nad Labem, Czech Republic, 401 13
Denmark
Research Site
Aalborg, Denmark, 9000
Research Site
Copenhagen, Denmark, 2100
Research Site
Odense, Denmark, 5000
Research Site
Århus C, Denmark, 8000
France
Research Site
Bayonne, France, 64109
Research Site
Bordeaux, France, 33075
Research Site
Clermont Ferrand Cedex 1, France, 63003
Research Site
Dijon cedex, France, 21079
Research Site
Le Mans, France, 72000
Research Site
Limoges Cedex, France, 87042
Research Site
Lyon Cedex 03, France, 69437
Research Site
Lyon Cedex 08, France, 69373
Research Site
Marseille cedex 5, France, 13385
Research Site
Montpellier Cedex 5, France, 34298
Research Site
Nice cedex 2, France, 06189
Research Site
Périgueux cedex, France, 24004
Research Site
Saint Priest en Jarez Cedex, France, 42270
Research Site
Saint Priest en Jarez, France, 42270
Research Site
Strasbourg, France, 67000
Germany
Research Site
Berlin, Germany, 13125
Research Site
Bielefeld, Germany, 33611
Research Site
Dresden, Germany, 01307
Research Site
Essen, Germany, 45276
Research Site
Frankfurt am Main, Germany, 60488
Research Site
Leipzig, Germany, 04103
Research Site
Magdeburg, Germany, 39104
Research Site
Mainz, Germany, 55131
Research Site
München, Germany, 81377
Research Site
München, Germany, 81737
Research Site
Oldenburg, Germany, 26133
Research Site
Schweinfurt, Germany, 97422
Greece
Research Site
Athens, Greece, 18547
Research Site
Heraklion - Crete, Greece, 71110
Research Site
Larissa, Greece, 41110
Research Site
Nea Kifissia, Athens, Greece, 14564
Research Site
Patra, Greece, 26500
Research Site
Thessaloniki, Greece, 54645
Research Site
Thessaloniki, Greece, 56429
Hungary
Research Site
Budapest, Hungary, 1097
Research Site
Budapest, Hungary, 1106
Research Site
Gyor, Hungary, 9023
Research Site
Nyiregyhaza, Hungary, 4400
Research Site
Szeged, Hungary, 6725
Research Site
Szolnok, Hungary, 5000
Italy
Research Site
Aviano PN, Italy, 33081
Research Site
Brescia, Italy, 25124
Research Site
Catania, Italy, 95122
Research Site
Firenze, Italy, 50134
Research Site
Napoli, Italy, 80131
Research Site
Pisa, Italy, 56126
Research Site
Roma, Italy, 00168
Mexico
Research Site
Mexico, Distrito Federal, Mexico, 14000
Research Site
Cuernavaca, Morelos, Mexico, 62290
Research Site
Distrito Federal, Mexico, 04380
Research Site
Toluca, Mexico, 50080
Poland
Research Site
Bialystok, Poland, 15-027
Research Site
Elblag, Poland, 82-300
Research Site
Gdansk, Poland, 80-219
Research Site
Konin, Poland, 62-500
Research Site
Lodz, Poland, 93-513
Research Site
Warszawa, Poland, 02-781
Portugal
Research Site
Aveiro, Portugal, 3814-501
Research Site
Guimaraes, Portugal, 4835-044
Research Site
Lisboa, Portugal, 1649-035
Research Site
Porto, Portugal, 4200-072
Research Site
Santa Maria da Feira, Portugal, 4520-211
Research Site
Vila Real, Portugal, 5000-508
Romania
Research Site
Alba Iulia, Romania, 510077
Research Site
Baia Mare, Romania, 430241
Research Site
Brasov, Romania, 500091
Research Site
Bucharest, Romania, 010719
Research Site
Bucharest, Romania, 011461
Research Site
Bucharest, Romania, 022328
Research Site
Cluj Napoca, Romania, 400015
Research Site
Cluj-Napoca, Romania, 400015
Research Site
Cluj-Napoca, Romania, 400058
Research Site
Lasi, Romania, 700106
Research Site
Timisoara, Romania, 300167
Russian Federation
Research Site
Chelyabinsk, Russian Federation, 454087
Research Site
Ivanovo, Russian Federation, 153013
Research Site
Kazan, Russian Federation, 420029
Research Site
Krasnodar, Russian Federation, 350040
Research Site
Moscow, Russian Federation, 115478
Research Site
Saint-Petersburg, Russian Federation, 197758
Research Site
Samara, Russian Federation, 443031
Research Site
Vladimir, Russian Federation, 600020
Slovakia
Research Site
Bardejov, Slovakia, 085 01
Research Site
Bratislava, Slovakia, 833 10
Research Site
Poprad, Slovakia, 058 01
Research Site
Trencin, Slovakia, 911 71
South Africa
Research Site
Groenkloof, Gauteng, South Africa, 0181
Research Site
Cape Town, South Africa, 7925
Research Site
Johannesburg, South Africa, 2193
Research Site
Kraaifontein, South Africa, 7570
Research Site
Pretoria, South Africa, 0002
Spain
Research Site
Oviedo, Asturias, Spain, 33011
Research Site
Barcelona, Cataluña, Spain, 08035
Research Site
L'Hospitalet de Llobregat, Cataluña, Spain, 08907
Research Site
Terrassa, Cataluña, Spain, 08221
Research Site
A Coruña, Galicia, Spain, 15006
Research Site
Pamplona, Navarra, Spain, 31008
Research Site
Madrid, Spain, 28050
Sweden
Research Site
Eskilstuna, Sweden, 631 88
Research Site
Stockholm, Sweden, 171 76
Switzerland
Research Site
Bellinzona, Switzerland, 6500
Research Site
Bern, Switzerland, 3010
Research Site
Chur, Switzerland, 7000
Turkey
Research Site
Ankara, Turkey, 06100
Research Site
Gaziantep, Turkey, 27100
Research Site
Istanbul, Turkey, 34390
Research Site
Izmir, Turkey, 35100
Ukraine
Research Site
Dnipropetrovsk, Ukraine, 49102
Research Site
Kharkiv, Ukraine, 61070
Research Site
Kherson, Ukraine, 73035
Research Site
Kyiv, Ukraine, 03115
Research Site
Lutsk, Ukraine, 43018
Research Site
Lviv, Ukraine, 79031
Research Site
Mariupol, Ukraine, 87500
Research Site
Sumy, Ukraine, 40022
Research Site
Uzhgorod, Ukraine, 88000
United Kingdom
Research Site
Belfast, United Kingdom, BT9 7AB
Research Site
Edinburgh, United Kingdom, EH4 2XU
Research Site
Guildford, United Kingdom, GU2 7XX
Research Site
Leicester, United Kingdom, LE1 5WW
Research Site
London, United Kingdom, NW1 2PQ
Research Site
London, United Kingdom, SE1 9RT
Research Site
London, United Kingdom, SW3 6JJ
Research Site
Manchester, United Kingdom, M20 4BX
Research Site
Newcastle Upon Tyne, United Kingdom, NE7 7DN
Research Site
Northwood, United Kingdom, HA6 2RN
Research Site
Salisbury, United Kingdom, SP2 8BJ
Research Site
Sutton, United Kingdom, SM2 5PT
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT01697072     History of Changes
Other Study ID Numbers: 20070622  2011-004923-11 
Study First Received: September 26, 2012
Last Updated: January 18, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Amgen:
Gastric Cancer
First Line Treatment Gastroesophageal Junction (GEJ)
Gastroesophageal Junction Cancer (GEJ)
GEJ Cancer

Additional relevant MeSH terms:
Adenocarcinoma
Stomach Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Cisplatin
Capecitabine
Epirubicin
Antibodies, Monoclonal
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 29, 2016